Taiho Oncology Patent-Cliff Exposure & CMS Drug Spending Portfolio

Taiho Oncology (US): 3 reconciled FDA prescription therapies, $398.5M 2024 CMS Part D & Medicaid spend, and $5,835 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$398.5M
2024 Medicare Part D Spend$342.3M
2024 Medicaid Spend$56.3M
California HCAI SB 17 FilingsSpecialty launch notice ($5,835 intro WAC)